Is It Time to Leave Behind the Concept of Asthma Control and Severity Steps?
Is It Time to Leave Behind the Concept of Asthma Control and Severity Steps? J Asthma. 2019 Nov 14;:1-3 Authors: Nannini LJ Abstract After 25 years of GINA, we need an overarching strategy. The resounding changes in GINA 2019 should be accompanied by another major change in general strategy of asthma management. The concept of control asthma and step strategy was established in 1997 by GINA; but still there is a great gap between GINA objectives and outcomes. O'Byrne and colleagues proposed a continuum of care approach; where patient-adjusted therapy would comprise both a controller and reliever (usually ICS/fast-acting LABA) in a single inhaler. We use a similar approach in our asthma centre.AbbreviationsGINAglobal initiative for asthmaICSinhaled corticosteroidsLABAlong acting beta2 agonistsPRNpro re nata (as needed)SABAsShort acting beta2 agonistsESCEuropean Society of CardiologyESHEuropean Society of HypertensionGPgeneral practitionersGOALThe Gaining Optimal Asthma ControL study.FABAfast acting beta agonists.FDAfood and drug administration. PMID: 31724457 [PubMed - as supplied by publisher]
The editors and staff of the Annals of Allergy, Asthma and Immunology would like to thank the flowing individuals who gave of their time to provide reviews of submitted manuscripts between January 1 and June 30, 2019. The high-quality manuscript reviews provided by these individuals is essentially to the peer review process so necessary for a journal like ours to provide scientifically sound as well as interesting and engaging articles for our readers. Thanks to each of you for your service.
Recent studies have highlighted the multidimensional effect of atopic dermatitis (AD) and urticaria. Patient burden for these conditions is largely driven by the intense itching, sleep disturbance, comorbidities, and mental health illness associated with these diseases.1-3 Immunologic, microbial, and epithelial interactions have been reported to play an important role in AD.4,5 Novel therapies and management approaches are targeting the mechanisms underlying AD and urticaria.6,7 The current issue of the Annals contains 3 outstanding reviews that update readers on the pathophysiology and evolving treatments for AD and chronic urticaria.
Mepolizumab may be an effective treatment option for patients with severe asthma and underlying eosinophilic chronic rhinosinusitis.BMC Pulmonary Medicine
Abstract Rhinoconjunctivitis is a public health problem that causes major illness and disability worldwide. Epidemiological studies intended to determine the burden of rhinoconjunctivitis in Kuwait are limited. Hence, this study sought to estimate the prevalence of rhinoconjunctivitis among adolescents in Kuwait and explore its association with different risk factors. Schoolchildren aged 11-14 years (n = 3,864) were enrolled in a cross-sectional study. Parents completed questionnaires regarding their children's clinical history and symptoms of rhinoconjunctivitis and relevant exposures. Associations ...
In conclusion, the study indicates that MFX relieves a depressive-like state in LPS-induced mice through the inhibition of the NLRP3 inflammasome and the enhancement of the neurogenesis pathway. PMID: 31814820 [PubMed - in process]